Treatment of atypical Haemolytic Uraemic Syndrome

On 30 January 2007, a new orphan medicinal product was registered into the community register of orphan medicinal products under the EU orphan designation number 425. The active ingredient is Complement factor H for treatment of atypical Haemolytic Uraemic Syndrome (aHUS) associated with an inherited abnormality of the complement system.